Approved studies using CPRD Data

Applications to access CPRD data for observational research are reviewed by the Independent Scientific Advisory Committee (ISAC). Approval by ISAC is required for researchers to carry out their proposed studies.

A summary of all ISAC-approved protocols, including a lay and technical summary of the proposed research, is published three months after researchers have access to the data to begin their study.

The table below includes all ISAC-approved protocols submitted to CPRD from 1st July 2015. Searches can be carried out using applicant names, approval date or by using key words within the protocol title. Protocols below are listed in order of date of approval.

 

ISAC Approval Date Title
21/12/2018 The pattern of incident fractures in patients with diabetes mellitus compared to matched controls
11/12/2018 Reproducible Evidence: Practices to Enhance and Achieve Transparency (REPEAT): Study 3 -Replication of "Non-persistence and non-adherence of patients with Type 2 Diabetes Mellitus in Therapy with GLP-1 Receptor Agonists: A Retrospective Analysis""
11/12/2018 All-cause and cardio-renal-metabolic mortality in people with or without type 2 diabetes: a comparative international trend study
05/12/2018 Reproducible Evidence: Practices to Enhance and Achieve Transparency (REPEAT): Study 20 - Replication of "Risk of Death and Cardiovascular Outcomes with Thiazolidinediones: A Study with the General Practice Research Database and Secondary Care Data"
30/11/2018 REPEAT Study 17 - Replication of "Risk of major bleeding and stroke associated with the use of vitamin K antagonists, nonvitamin K antagonist oral anticoagulants and aspirin in patients with atrial fibrillation: a cohort study"
30/11/2018 Prescriptions for antibiotics in childhood and risk of inflammatory bowel disease: A matched case-control study in the UK Clinical Practice Research Datalink
26/11/2018 The impact of knee replacement on mortality in the presence of chronic disease
22/11/2018 Trends in the prescribing of opioids for non-malignant pain in UK primary care: a descriptive study
21/11/2018 Missed opportunities for limb salvage in patients undergoing major amputation - a retrospective cohort study of the clinical practice research datalink
19/11/2018 Risk of hospitalised Influenza, England, 2000-2017
19/11/2018 Reproducible Evidence: Practices to Enhance and Achieve Transparency (REPEAT): Study 18-Replication of "Risk of Myocardial infarction in Patients with Atrial Fibrillation using vitamin K antagonists, aspirin or direct acting oral anticoagulants"
19/11/2018 DPP-4 inhibitor dose selection according to Summaries of Product Characteristics: A contemporary experience from the UK General Practice
16/11/2018 An external validation of the SMART vascular event risk prediction model in a secondary prevention UK routine care cohort
14/11/2018 Reproducible Evidence: Practices to Enhance and Achieve Transparency (REPEAT) Study 19: Replication of "Long-term use of dipeptidyl peptidase-4 inhibitors and risk of fracture: A retrospective population-based cohort study."
13/11/2018 Proton pump inhibitor use and the risk of myocardial infarction: a nested case-control study in the UK Clinical Practice Research Datalink.
06/11/2018 Impact of recurrent hospitalization events on mortality in patients with Heart Failure: a retrospective analysis of a UK database
06/11/2018 A retrospective examination of glaucoma patients in the CPRD database with contraindications for anti-glaucoma beta-blocker therapy
06/11/2018 Reproducible Evidence: Practices to Enhance and Achieve Transparency (REPEAT): Study 16 - "Use of tamoxifen and aromatase inhibitors in a large population-based cohort of women with breast cancer"
05/11/2018 Maternal and perinatal characteristics associated with Respiratory Tract Infection (RTI) healthcare utilisation and death in a birth cohort using the CPRD database and other linked databases
05/11/2018 Evaluation of probable treatment indications for the prescription of oral glycopyrronium in the United Kingdom - both licensed and off-label